# EDGAR Filing Document

**Accession Number:** 0001176309
**File Stem:** 0001213900-25-101825
**Filing Date:** 2025-10
**Character Count:** 36457
**Document Hash:** f29207df6bdb1d45d5e1a34c015bd002
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-101825.hdr.sgml**: 20251024

**ACCESSION NUMBER**: 0001213900-25-101825

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251020

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Termination of a Material Definitive Agreement

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251024

**DATE AS OF CHANGE**: 20251023

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ORAMED PHARMACEUTICALS INC.
- **CENTRAL INDEX KEY:** 0001176309
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 980376008
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35813
- **FILM NUMBER:** 251414042

**BUSINESS ADDRESS:**
- **STREET 1:** 1185 AVENUE OF THE AMERICAS, 3RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
- **BUSINESS PHONE:** 646-844-1164

**MAIL ADDRESS:**
- **STREET 1:** 1185 AVENUE OF THE AMERICAS, 3RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Integrated Security Technologies, Inc.
- **DATE OF NAME CHANGE:** 20040614

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IGUANA VENTURES LTD
- **DATE OF NAME CHANGE:** 20020625

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of** 

**the Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **October 20, 2025**

**ORAMED PHARMACEUTICALS INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **delaware** | **001-35813** | **98-0376008** |
| (State or Other Jurisdiction of<br> Incorporation) | (Commission File Number) | (IRS Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **1185 Avenue of the Americas, Third Floor,<br> New York, New York** | **10036** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**844-967-2633**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading symbol | Name of each exchange on which registered |
| **Common Stock, par value $0.012** | **ORMP** | **The Nasdaq Capital Market,<br> Tel Aviv Stock Exchange** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

**Item 1.01 Entry Into a Material Definitive Agreement**

On October 20, 2025, Oramed Pharmaceuticals Inc. (the "Company") entered into a share repurchase agreement (the "Repurchase Agreement") with Hefei Tianhui Biotech Co., Ltd. ("HTIT Biotech") pursuant to which HTIT Biotech agreed to sell back to the Company an aggregate of 1,155,367 shares of common stock, par value $0.012 per share of the Company (the "Shares") to the Company at a purchase price of $2.23 per Share for an aggregate price of $2,576,468.41 (the "Repurchase"). The closing of the Repurchase occurred on October 20, 2025, and the Shares have been cancelled and retired.

The foregoing summary of the Repurchase Agreement is not complete and is qualified in its entirety by the full text of the Repurchase Agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

**Item 1.02 Termination of a Material Definitive Agreement**

As previously reported on Current Report on Form 8-K, on January 22, 2024, the Company and its wholly-owned subsidiary, Oramed Ltd., entered into a Joint Venture Agreement (the "JV Agreement") with HTIT Biotech and Technowl Limited, a wholly-owned indirect subsidiary of HTIT Biotech ("HTIT Sub," and together with HTIT Biotech, collectively "HTIT"), pursuant to which, subject to the terms and conditions set forth in the JV Agreement, the parties agreed to establish a joint venture based on Company's oral drug delivery technology.

Pursuant to the JV Agreement, as amended by that certain Ancillary Agreement Completion Protocol and Supplemental Agreement (the "Supplemental Agreement"), dated as of February 2025, the initial closing deadline of the transactions contemplated by the JV Agreement was set to be April 30, 2025, which was subsequently extended. However, HTIT was unable to satisfy the closing conditions under the JV Agreement and the Supplemental Agreement, and on October 23, 2025, the Company provided notice to HTIT to terminate the JV Agreement and the Supplemental Agreement, effective as of the date of the notice.

**Item 2.02 Results of Operations and Financial Condition**

On October 23, 2025, the Company issued a letter to its shareholders (the "Shareholder Letter"), which contains certain unaudited, preliminary and estimated financial information of the Company as of September 30, 2025 (the "Financial Information").

 ****

***Cautionary Statement Regarding the Financial Information***

The Company cautions investors and potential investors not to place undue reliance upon the Financial Information contained in the Shareholder Letter, which was not prepared for the purpose of providing the basis for an investment decision relating to any of the Company's securities. The Financial Information was not audited by independent accountants and is subject to future adjustment and reconciliation. There can be no assurance that, from the perspective of an investor or potential investor in the Company's securities, the Financial Information disclosed in the Shareholder Letter is complete. The Company has not yet completed its quarter-end financial close processes for the fiscal quarter ended September 30, 2025, and as such, the Financial Information is based on financial information currently available to the Company, including certain assumptions and estimates by management, and should be considered preliminary. As such, the Company's actual results for the quarter ended September 30, 2025, may materially vary from the Financial Information. The Financial Information should not be viewed as indicative of future results.

The information in Item 2.02 of this Current Report on Form 8-K (including the Financial Information contained in Exhibit 99.1 attached hereto) is being furnished and shall not be deemed to be filed for purposes of Section 18 of the Exchange Act or otherwise be subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filing.

**Item 8.01 Other Events.**

A copy of the Shareholder Letter is attached hereto as Exhibit 99.1 and is incorporated herein by reference, except for the Financial Information contained therein, as discussed under Item 2.02 of this Current Report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1 | [Share Repurchase Agreement, dated October 20, 2025, by and between the Company and Hefei Tianhui Biotech Co., Ltd.](ea026231901ex10-1_oramed.htm) |
| 99.1 | [Shareholder Letter, dated October 23, 2025](ea026231901ex99-1_oramed.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **ORAMED PHARMACEUTICALS INC.** | **ORAMED PHARMACEUTICALS INC.** |
| By: | /s/ Nadav Kidron |
| Name: | Nadav Kidron |
| Title: | President and CEO |

---

October 23, 2025

## Exhibit 10.1

**Exhibit 10.1**

**SHARE REPURCHASE AGREEMENT**

SHARE REPURCHASE AGREEMENT (this "<u>Agreement</u>") dated as of October 20, 2025, between Hefei Tianhui Biotech Co., Ltd. ("<u>Seller</u>") and Oramed Pharmaceuticals Inc. ("<u>Repurchaser</u>").

WHEREAS, Seller desires to sell an aggregate of 1,155,367 shares of common stock, par value $0.012 per share, of Repurchaser (the "<u>Shares</u>") that it owns as of the date of this Agreement, on the terms and conditions set forth herein; and

NOW, THEREFORE, in consideration of the premises and the mutual covenants contained in this Agreement, the parties agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Sale and Repurchase of the Shares</u>. Subject to the terms
and conditions hereof and in reliance upon the representations and warranties contained herein, Seller agrees to sell to Repurchaser,
and Repurchaser agrees to repurchase from Seller, the Shares for an aggregate price of $2,576,468.41 at a purchase price of $2.23 per
Share (the "Purchase Price"). The closing of the transaction (the " Closing ") shall occur on the same day of signing this agreement (the " Closing
Date "). At the Closing:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Seller shall have delivered or cause to be delivered to Repurchaser's
transfer agent, Continental Stock Transfer & Trust ("Continental") the stock certificate(s) representing the Shares to
be sold, duly endorsed for transfer to Repurchaser.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Upon the execution of this Agreement, Repurchaser shall initiate
the wire transfer of the aggregate Purchase Price for the Shares promptly. Repurchaser shall pay the Purchase Price by wire transfer
of immediately available funds to the account information set forth in **Exhibit 1**. If the payment is delayed by a failure by Repurchaser
to take any action reasonably necessary to facilitate the wire transfer for more than five (5) Business Days after signing of this Agreement,
this Agreement shall be automatically terminated, and the share transfer shall be cancelled.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Upon the execution of this Agreement, Seller shall prepare
an instruction letter set forth in Exhibit 2 (the "Instruction Letter"). Promptly after Repurchaser has irrevocably wire
transferred the aggregate Purchase Price to Seller and provided the wire transfer remittance to Seller, and the execution of this Agreement,
Seller shall provide the Instruction Letter to Continental so Continental may effect the transfer of the Shares from Seller to Repurchaser.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Acknowledgments, Representations and Warranties of Seller</u>.
Seller hereby represents and warrants to Repurchaser that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Seller owns the Shares beneficially and of record, free and
clear of any liens, security interests, restrictions, encumbrances, pledges, claims or charges of any nature whatsoever, and no person
has a right to acquire or direct the disposition, or holds a proxy or other right to vote or direct the vote, of the Shares. Upon delivery
to Repurchaser of the certificates representing such Shares in accordance with Section 1 hereof, good and marketable title thereto shall
be transferred to Repurchaser, free and clear of any liens, security interests, restrictions, encumbrances, pledges, claims or charges
of any nature whatsoever other than those imposed by applicable federal and state securities laws. Except for this Agreement, there is
no option, warrant, right, call, proxy, agreement, commitment or understanding of any nature whatsoever, fixed or contingent, that directly
or indirectly (i) calls for the sale, pledge or other transfer or disposition of any of the Shares, any interest therein or any rights
with respect thereto, or relates to the voting, disposition, exercise, conversion or control of the Shares, or (ii) obligates Seller
to grant, offer or enter into any of the foregoing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Seller has full power and authority to execute, deliver and
perform this Agreement. This Agreement has been duly authorized by all necessary action on the part of Seller and does not require the
consent or approval of any person or entity, including any government agency. This Agreement has been duly executed and delivered by
Seller, and (assuming due authorization, execution and delivery by Buyer) this Agreement constitutes the legal, valid and binding obligation
of Seller, enforceable against Seller in accordance with its terms. The execution, delivery and performance by Seller of this Agreement,
and the carrying out of the transactions provided for in this Agreement, do not and will not: (a) violate or conflict with any judgment,
order, decree, statute, law, ordinance, rule or regulation applicable to Seller; (b) create any lien on any of the Shares under any indenture,
mortgage, lien, agreement, contract, commitment or instrument to which Seller is a party; or (c) conflict any violation of, or default
under, or give rise to a right of termination, acceleration or modification of any obligation or loss of any benefit under any contract
or other instrument to which Seller is a party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Seller had initially purchased or received the Shares directly
from Repurchaser in a private placement exempt from registration under the Securities Act of 1933, as amended (the " <u>Securities Act</u> ") and has owned the Shares continuously since their initial acquisition for Repurchaser.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Seller hereby expressly acknowledges and agrees that (i)
the Purchase Price is fair, equitable and valid, and (ii) the price of Repurchaser's common stock is subject to market forces,
which may result in variances in the value thereof, which variances may be significant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Seller hereby expressly acknowledges that Repurchaser may
be in possession of material non-public information regarding Repurchaser not known to the Seller (collectively, the " <u>Excluded Information</u> "). The Seller expressly acknowledges that the Excluded Information may be indicative of a value of the Shares that
is substantially lower than the Purchase Price or otherwise adverse to the Seller and such Excluded Information may be material to Seller's
decision to sell the Shares. Seller represents that it has not requested the Excluded Information and agrees that Repurchaser shall not
be obligated to disclose any Excluded Information or have any liability with respect to any such non-disclosure.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Representations and Warranties of Repurchaser. Repurchaser
hereby represents and warrants to Seller that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Repurchaser has full corporate power and authority to execute,
deliver and perform this Agreement. The execution and delivery of this Agreement and the consummation of the transactions contemplated
hereby have been duly authorized by all necessary corporate action on the part of Repurchaser.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Repurchaser has sufficient available funds to pay the Purchase
Price on the Closing Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Mutual Release</u>. Each party hereby waives and releases
and promises never to assert any claims or causes of action, whether or not now known, against the other party or its predecessors, successors
or past or present subsidiaries, officers, directors, agents, partners, members, managers, employees, present and future stockholders,
assigns and affiliates thereof (collectively, with respect to such other party, its "Released Parties") from any and all
actions, suits, claims, demands, debts, sums of money, accounts, reckonings, bonds, bills, covenants, contracts, controversies, promises,
judgments, liabilities or obligations of any kind whatsoever in law or equity and causes of action of every kind and nature, or otherwise
(including, without limitation, claims for damages, costs, expenses and attorneys', brokers' and accountants' fees
and expenses) arising out of or related to the sale and repurchase of the Shares pursuant to this Agreement, which such party can, shall
or may have against the other party or its Released Parties, whether known or unknown, suspected or unsuspected, unanticipated as well
as anticipated and that now exist or may hereafter accrue (other than with respect to a breach of a covenant by the other party under
this Agreement).5. <u>Miscellaneous</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Survival. All agreements, representations and warranties
contained herein or made in writing on behalf of any party hereto in connection with the transactions contemplated hereby shall survive
the execution and delivery of this Agreement according to their terms without limit as to duration.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Governing Law. This Agreement shall be construed under and
governed by, and construed in accordance with, the laws of the State of New York applicable to contracts executed in and to be performed
in that state and without regard to any applicable conflict of laws principles.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Dispute Resolution. Any dispute arising out of or relating
to this Agreement shall be finally settled by arbitration administered by the International Chamber of Commerce (ICC) in accordance with
its Arbitration Rules. The seat of arbitration shall be New York City, New York. The language of the arbitration shall be English.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Seller will not make any public disclosures or filings in
connection with the transactions contemplated by this Agreement, whether voluntary or required pursuant to the Securities Exchange Act
of 1934, as amended, and the rules and regulations promulgated thereunder, unless Seller has furnished a copy thereof to Repurchaser
for its review prior to such disclosure or filing and Repurchaser approves such disclosure or filing, which approval shall not be unreasonably
withheld, conditioned or delayed

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Legal and Equitable Remedies.
In the event Seller fails to deliver the Shares or to provide the necessary instructions or documentation to Continental as required
under Section 1, Repurchaser shall be entitled to enforce such obligations through specific performance or other appropriate equitable
relief to compel such delivery or action, provided that Repurchaser shall have performed all of its obligations under this Agreement,
including the payment obligations under Section 1(b). This right shall be without prejudice to any other remedies available to Repurchaser
under applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Validity and Severability. If any provision of this Agreement
shall be held to be illegal, invalid or unenforceable under any applicable law, then such contravention or invalidity shall not invalidate
the entire Agreement. Such provision shall be deemed to be modified to the extent necessary to render it legal, valid and enforceable,
and if no such modification shall render it legal, valid and enforceable, then this Agreement shall be construed as if not containing
the provision held to be illegal, invalid or unenforceable and the rights and obligations of the parties hereto shall be construed and
enforced accordingly.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) Expenses. Whether or not the transactions contemplated by
this Agreement are consummated, each of the parties hereto shall pay their respective fees and expenses incurred in connection herewith.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) Entire Agreement. This Agreement contains the sole and entire
agreement and understanding of each of the parties with respect to the subject matter hereof, and any and all other discussions, negotiations,
representations, commitments, understandings, promises, and agreements relating to the entire subject matter of this Agreement are merged
into this Agreement. Each party to this Agreement further acknowledges and agrees that no other agreement or representation, whether
written, oral, or implied, other than those expressly contained or referred to in this Agreement, shall be deemed to exist or bind the
parties with respect to the entire subject matter of this Agreement. Each party represents and acknowledges that in executing this Agreement,
such party does not rely on, has not relied on, and specifically disavows any reliance on any communications, promises, statements, inducements,
or representation(s), oral or written, by any other party or its agents except as expressly contained in this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Amendment. This Agreement may not be amended or modified
except by an instrument in writing signed by each of the parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) Counterparts. This Agreement may be executed and delivered
(including by electronic or facsimile transmission) in one or more counterparts, and by the parties hereto in separate counterparts,
each of which when executed and delivered shall be deemed to be an original, but all of which taken together shall constitute one and
the same agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) Headings. The headings of the sections of this Agreement
are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) Construction. As used in this Agreement, the words "herein,"
"hereof" and "hereunder" and other words of similar import refer to this Agreement as a whole and not to any
particular article, section, paragraph or other subdivision.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) Facsimile and Electronic Signatures. A facsimile copy of
a signature or a signature transmitted electronically (e.g., by .pdf) shall be deemed an original signature for purposes of enforcing
this Agreement.

IN WITNESS WHEREOF, Seller and Repurchaser have executed this Agreement as of the day and year first above written.

---

| | | |
|:---|:---|:---|
| Hefei Tianhui Biotech Co., Ltd. | Hefei Tianhui Biotech Co., Ltd. | Hefei Tianhui Biotech Co., Ltd. |
| By: | /s/ (Company Seal of Hefei Tianhui Biotech Co., Ltd was affixed) | /s/ (Company Seal of Hefei Tianhui Biotech Co., Ltd was affixed) |
| Oramed Pharmaceuticals Inc. | Oramed Pharmaceuticals Inc. | Oramed Pharmaceuticals Inc. |
| By: | /s/ Avi Gabay | /s/ Avi Gabay |
|  | Name: | Avi Gabay |
|  | Title: | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, <br> Significant Investment Appreciation, and Upcoming Growth Initiatives**

● *Oramed Advancing Oral Insulin Program Independently; Announces Launch of New U.S. Trial* 

 

● *Diversified Investment Portfolio Delivers Strong Returns* 

 

● *Company Accelerating Growth Through Strategic Partnerships, Innovation, and Value-Driven Expansion* 

 

● *Company Reaffirms Commitment to Rewarding Shareholders, Including Plans for a One-Time Dividend* 

**NEW YORK, October 23, 2025** -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) ("Oramed" or the "Company" or "we"), a clinical-stage pharmaceutical company, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron.

Dear Shareholders,

I am pleased to share with you some of the significant developments we have seen across Oramed's operations and strategic initiatives. Over the past year, we have advanced our core programs while simultaneously building a diversified portfolio of opportunities that demonstrate our commitment to creating long-term shareholder value.

We have leveraged our strengths, including our deep industry relationships, insights, and operational expertise, to identify and capitalize on high-conviction investment opportunities across the biomedical landscape. This diversified approach has generated substantial returns while maintaining our focus on advancing our refined oral insulin program based on the high-responder subgroups we identified through extensive data analysis.

<u>Oral Insulin Program:</u>

Following our extensive deep-dive analysis of Phase 2 and Phase 3 data, we have identified high-responder subgroups that demonstrated particularly encouraging results. These subgroups—including participants with lower BMI and older demographics—showed the possibility of achieving over 1% reduction in HbA1c, a clinically meaningful outcome that potentially strengthens our regulatory and commercial positioning.

We are initiating a 60-patient, US-based trial. We believe this approach will allow us to validate the robustness of our oral insulin formulation while providing valuable data to potential partners. The trial was designed to use the smallest adequately powered population expected to obtain such validation in what we believe to be the shortest time possible, providing a cost-effective way to generate additional compelling evidence and refine our patient selection criteria for future potential regulatory submissions.

The previously announced joint venture with Hefei Tianhui Biotech Co. Ltd. ("HTIT"), has been terminated due to HTIT's inability to satisfy the closing financial conditions under the agreement. However, the Company plans to continue its oral insulin development program independently, thus allowing it to maintain full control and momentum on this critical program without external dependencies.

<u>Investment Portfolio:</u>

Over the past two years, Oramed has made strategic investments in a diversified portfolio of innovative biomedical companies, each selected for their potential to generate substantial returns while complementing our core competencies:

**Scilex Holdings** ("Scilex") In September 2023, we provided a loan to Scilex in the amount of $99.5 million. To date, this structured investment has returned $95.5 million, with additional expected returns of over $60 million anticipated in the next 12 months, plus ongoing royalties for the next 9 years. Total returns could reach approximately $170 million, with potential for additional upside from the convertible note and other components of the transaction structure. Further information about Scilex is available on their website: https://www.scilexholding.com

**Alpha Tau Medical Ltd** ("Alpha Tau") Alpha Tau is pioneering a revolutionary approach to cancer treatment through its Alpha DaRT (Diffusing alpha-emitters Radiation Therapy) technology. This innovative alpha radiation therapy intends to deliver a powerful, highly localized treatment that destroys tumors while minimizing damage to surrounding healthy tissue. We identified Alpha Tau as an exceptional investment opportunity due to their groundbreaking technology platform, strong clinical progress, and significant commercial potential across multiple cancer indications.

We made an initial investment of $36.9 million in Alpha Tau on April 24, 2025, purchasing 14.1 million shares at $2.612 per share as part of a deal that included board representation. Recognizing the significant potential, we subsequently purchased approximately 259,000 additional shares in the open market through September 30, 2025, for $846,000 at an average price of $3.27 per share bringing our total investment to $37.7 million. Based on the closing price of $4.51 per share on September 30, 2025, our total position of 14.4 million shares is valued at approximately $64.8 million, a $27.1 million gain.

Beyond the immediate appreciation, we believe Alpha Tau represents an exceptional long-term opportunity with multiple transformative clinical and commercial inflection points ahead. We believe their revolutionary alpha radiation therapy technology positions them for significant value creation as they advance through pivotal clinical milestones and move toward commercialization across multiple indications.

As part of our involvement, we entered into an investor relations and business advisory agreement valued at $3 million over 3 years plus warrants to purchase up to 3.2 million shares at exercise prices ranging from $3.47 to $3.90 per share. Further information about Alpha Tau Medical is available on their website: https://www.alphatau.com/Shareholders interested in receiving updates directly from Alpha Tau can visit their investor relations page at https://www.alphatau.com/news-pr.

**BioXcel Therapeutics , Inc.** ("BioXcel") BioXcel is pioneering an innovative approach to drug development by leveraging artificial intelligence to identify and advance novel therapies in neuroscience and immuno-oncology. We invested $7 million in BioXcel on March 4, 2025 and as of September 30, 2025 have realized $6.25 million through partial sales. We currently maintain an open position of 700,000 warrants at a $4.20 strike price, providing continued exposure to their promising AI-driven drug discovery pipeline. Further information about BioXcel is available on their website: https://www.bioxceltherapeutics.com/

**Pelthos Therapeutics Inc.** ("Pelthos") Pelthos, a commercial-stage revenue-generating biotech company, is developing novel drug delivery platform technologies with significant potential across multiple therapeutic areas.

We invested $1.5 million, purchasing 150,000 shares at $10 per share on July 1, 2025. Based on a closing price of $28 per share on September 30, 2025, our position is currently realizing a 180% gain. This $4.2 million current valuation reflects Pelthos's strong execution and market validation of their novel drug delivery platform technologies. Further information about BioXcel is available on their website: https://pelthos.com/

**Additional Investments:** In addition to the investments detailed above, we maintain small positions in earlier-stage biotech investments that continue to be part of our diversified portfolio of strategic investments. Additionally, as part of our capital management strategy, we have invested and loaned approximately $32.4 million in real estate and loans with real estate collateral.

<u>Dividend Update:</u>

In connection with our previously announced joint venture, we discussed providing shareholders with a one-time dividend. While we have decided to continue our oral insulin program independently without the spin-off, we remain committed to rewarding our shareholders.

<u>Upcoming Growth Initiative</u>

Building on our investment track record, we are actively pursuing partnerships with strong companies possessing significant potential, as we have demonstrated with Alpha Tau Medical, Scilex, and our other portfolio companies. We leverage our extensive network, regulatory expertise, and business development capabilities to actively shape these companies' growth trajectories and help unlock their full market potential. We are continuously working to identify and execute on potential opportunities that can drive substantial value creation.

 ****

***In Conclusion, we believe the numbers speak for themselves:*** In January 2023, following our Phase 3 trial that did not meet its primary endpoints, we had $155.7 million in cash and cash equivalent. In less than three years, while investing $17.8 million in R&D to advance our refined oral insulin program and share buybacks, we have simultaneously grown our total cash and assets to approximately $210 million as of September 30, 2025 (unaudited)- demonstrating our ability to create substantial value through strategic capital deployment.

We believe Oramed stands at a unique inflection point, with our core oral insulin program showing renewed promise through our refined subgroup analysis while our investment portfolio demonstrates our ability to identify and capitalize on emerging opportunities. We believe our multi-faceted approach, combining clinical development, partnerships, and prudent capital deployment across diversified assets, positions us to create sustainable value across diverse market opportunities.

Thank you for your continued support as we execute on this expanded growth strategy. We look forward to sharing more detailed updates on our progress in the coming quarters.

Sincerely,

Nadav Kidron<br> Chief Executive Officer

**About Oramed Pharmaceuticals**

Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Oramed's novel Protein Oral Delivery (POD™) technology is designed to protect drug integrity and increase absorption. For more information, please visit www.oramed.com.

**Forward-looking statements:** This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements when we discuss our trial plans, expected returns from our investment portfolio, our growth initiatives, potential partnerships, dividend plans, and our ability to create shareholder value through our diversified approach. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval; competition from other pharmaceutical or biotechnology companies; market volatility affecting our investment portfolio; our ability to realize expected returns from Scilex and other investments; and our ability to identify and execute partnerships. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions or updates to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

**Company Contact:**

+1-844-9-ORAMED<br> ir@oramed.com